| Title: | Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting |
| Authors: | Kariya, Shin Browse this author |
| Shimizu, Yasushi Browse this author |
| Hanai, Nobuhiro Browse this author |
| Yasumatsu, Ryuji Browse this author |
| Yokota, Tomoya Browse this author |
| Fujii, Takashi Browse this author |
| Tsukahara, Kiyoaki Browse this author |
| Yoshida, Masafumi Browse this author |
| Hanyu, Kenji Browse this author |
| Ueda, Tsutomu Browse this author |
| Hirakawa, Hitoshi Browse this author |
| Takahashi, Shunji Browse this author |
| Ono, Takeharu Browse this author |
| Sano, Daisuke Browse this author |
| Yamauchi, Moriyasu Browse this author |
| Watanabe, Akihito Browse this author |
| Omori, Koichi Browse this author |
| Yamazaki, Tomoko Browse this author |
| Monden, Nobuya Browse this author |
| Kudo, Naomi Browse this author |
| Arai, Makoto Browse this author |
| Yonekura, Shuji Browse this author |
| Asakage, Takahiro Browse this author |
| Fujiwara, Akinori Browse this author |
| Yamada, Takayuki Browse this author |
| Homma, Akihiro Browse this author →KAKEN DB |
| Keywords: | Nivolumab |
| Recurrent or metastatic head and neck cancer |
| Immune microenvironment |
| Cetuximab |
| Neck dissection |
| Issue Date: | Jun-2021 |
| Publisher: | Springer |
| Journal Title: | International journal of clinical oncology |
| Volume: | 26 |
| Start Page: | 1049 |
| End Page: | 1056 |
| Publisher DOI: | 10.1007/s10147-021-01900-4 |
| Abstract: | Background To examine the effect of prior use of cetuximab and neck dissection on the effectiveness of nivolumab, we conducted a large-scale subgroup analysis in Japanese patients with recurrent/metastatic head and neck cancer. Methods Data on the effectiveness of nivolumab were extracted from patient medical records. All patients were analyzed for effectiveness by prior cetuximab use. In the analyses for prior neck dissection, only patients with locally advanced disease were included. Results Of 256 patients analyzed, 155 had received prior cetuximab. Nineteen of 50 patients with local recurrence underwent neck dissection. The objective response rate was 14.7 vs 17.2% (p = 0.6116), median progression-free survival was 2.0 vs 3.1 months (p = 0.0261), and median overall survival was 8.4 vs 12 months (p = 0.0548) with vs without prior cetuximab use, respectively. The objective response rate was 23.1 vs 25.9% (p = 0.8455), median progression-free survival was 1.8 vs 3.0 months (p = 0.6650), and median overall survival was 9.1 vs 9.9 months (p = 0.5289) with vs without neck dissection, respectively. Conclusions These findings support the use of nivolumab for patients with recurrent/metastatic head and neck cancer regardless of prior cetuximab use or neck dissection history. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/81599 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
